

Press Release, 5 February 2007

CMC Biopharmaceuticals and Biotest Announce Manufacturing Agreement for BT-062 Antibody

Copenhagen, Denmark; February 5 2007 – CMC Biopharmaceuticals A/S, a Copenhagen based contract manufacturing organization, and Biotest AG a developer of pharmaceutical, biotherapeutic and diagnostic products based in Dreieich, Germany announced today that they have entered into a manufacturing agreement for the cGMP production of BT-062 antibody. The product will be manufactured at CMC's facility in Copenhagen, Denmark, for clinical supply.

CMC's facility is state-of-the-art and designed and constructed specifically for contract manufacturing services in full cGMP compliance. Purpose-built to operate with a high degree of flexibility, segregation, and traceability, it is capable of handling simultaneous multi-product manufacturing. The facility has received approval from the Danish Medicines Agency on behalf of EMEA for manufacture of Active Pharmaceutical Ingredients from both microbial and mammalian production systems for Clinical Trials and In-Market supply.

Mr. Mads Laustsen, CMC's CEO, remarked on the agreement: "CMC is delighted to have formed this partnership with Biotest for the manufacture of this promising drug candidate for the treatment of multiple myeloma. This agreement continues to validate CMC's expertise in process development and cGMP manufacturing."

About CMC Biopharmaceuticals A/S

Based in Copenhagen, Denmark, CMC is a contract development and manufacturing organisation with sales offices located in both Europe and the U.S.

CMC specializes in process and analytical development as well as the scale-up and cGMP manufacture of Active Pharmaceutical Ingredients for pre-clinical, clinical trials and in-market production. CMC's competitive strength is centred on the flexibility it can offer customers combined with the extensive experience of its management and key personnel in the field of biopharmaceutical manufacture and development.

About Biotest AG

Biotest AG, Dreieich, Germany, is a company that researches and manufactures pharmaceutical, biotherapeutic and diagnostic products and has specialized in immunology and haematology. In its Pharmaceutical segment, Biotest develops immunoglobulins, clotting factors and albumins based on human blood plasma. These are used for diseases of the immune system or haematopoietic system. In addition, Biotest also researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and blood cancer. The Diagnostic segment spans reagents and serology and microbiology systems which are used, for example, in blood transfusions. Biotest has around 1,100 employees worldwide and its shares are listed in the Frankfurt Stock Exchange's Prime Standard.

Contact:

Richard Hart, VP Business Development
CMC Biopharmaceuticals A/S
Tel +44 1491 681 823
rh@cmcbio.com
www.cmcbio.com